A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00022672
First received: August 10, 2001
Last updated: June 7, 2013
Last verified: June 2013
  Purpose

This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.


Condition Intervention Phase
Breast Cancer
Drug: trastuzumab (Herceptin®)
Drug: anastrazole (Arimidex®)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: 24 Months, End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented.


Secondary Outcome Measures:
  • Percentage of Participants With Clinical Benefit [ Time Frame: 24 Months, End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Clinical Benefit was defined as stable disease for ≥ six months or complete response or partial response.

  • Duration of Response at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

  • Time to Response at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

  • Overall Survival at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Overall Survival is defined as the number of days from randomization to death.

  • Percentage of Participants With Two-Year Survival [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
  • Percentage of Participants With Overall Tumor Response at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

  • Percentage of Participants With Best Tumor Response at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

  • Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline [ Time Frame: Baseline, Final Visit (Up to 24 Months) ] [ Designated as safety issue: No ]

    Participants rated their performance status using the ECOG Questionnaire on the following scale: 0=Fully active, perform all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature; 2=Ambulatory, capable of self-care, unable to carry out any work activities, up and about more than >50% of waking hours; 3=Capable of limited self-care, confined to bed or chair >50% of waking hours; 4=Completely disabled, not capable of any self-care, totally confined to bed or chair; 5=Dead.

    The percentage of participants in the following categories:

    Improved: Score decrease from baseline. Unchanged: Score the same as baseline. Worse: Score increase from baseline.


  • Duration of Response at End of Study [ Time Frame: End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Duration of response was defined as the number of days from the day complete response or partial response was first noted to the day of progression of disease, death or last follow-up.

  • Time to Response at End of Study [ Time Frame: End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Time to response was defined as the number of days from the day of randomization to the day complete response or partial response was first noted.

  • Percentage of Participants With Overall Tumor Response at End of Study [ Time Frame: End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Overall Response was defined as either complete response or partial response.

  • Percentage of Participants With Best Tumor Response at End of Study [ Time Frame: End of Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Tumor Response levels were determined by the investigator and an Independent Response Evaluation Committee and Reconciled. Best Response was defined as the best response a patient achieves in the study.

  • Number of Participants With Adverse Events [ Time Frame: Throughout the Study (Up to 5 years) ] [ Designated as safety issue: No ]
    Number of participants with adverse events as a measure for safety as assessed by the collection of adverse events, laboratory tests for Hematology and Serum Chemistry, clinical assessments and cardiac monitoring.


Enrollment: 208
Study Start Date: January 2001
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: trastuzumab + anastrozole
Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
Drug: trastuzumab (Herceptin®)
4mg/kg iv loading dose, followed by 2mg/kg iv weekly
Other Name: Herceptin®
Drug: anastrazole (Arimidex®)
1 mg tablet taken orally daily
Other Name: Arimidex®
Active Comparator: anastrozole
1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
Drug: anastrazole (Arimidex®)
1 mg tablet taken orally daily
Other Name: Arimidex®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • postmenopausal women;
  • metastatic breast cancer suitable for endocrine therapy;
  • positive hormone receptor status;
  • Human epidermal growth factor receptor 2 (HER2) overexpression.

Exclusion Criteria:

  • patients on hormone replacement therapy;
  • previous chemotherapy for metastatic disease;
  • uncontrolled cardiac disease and history of cardiac failure.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00022672

  Show 132 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Genentech, Inc.
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00022672     History of Changes
Obsolete Identifiers: NCT00112450
Other Study ID Numbers: BO16216
Study First Received: August 10, 2001
Results First Received: April 2, 2013
Last Updated: June 7, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Anastrozole
Aromatase Inhibitors
Trastuzumab
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014